# Taxoprexin Treatment for Advanced Skin Melanoma

> **NCT00249262** · PHASE2 · COMPLETED · sponsor: **American Regent, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Taxoprexin

## Key facts

- **NCT ID:** NCT00249262
- **Lead sponsor:** American Regent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00249262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00249262, "Taxoprexin Treatment for Advanced Skin Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00249262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*